DoorDash, Inc. (DASH) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10%. A quarter ago, it was expected that this company would post earnings of $0.34 per share when it actually produced earnings of $0.33, delivering a surprise of -2.94%.Over the last four quarters, the company has surp ...

Core Insights - Marriott International reported quarterly earnings of $2.32 per share, exceeding the Zacks Consensus Estimate of $2.27 per share, and showing an increase from $2.13 per share a year ago, representing an earnings surprise of 2.20% [1] - The company posted revenues of $6.26 billion for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.18%, but up from $5.98 billion year-over-year [2] - The stock has underperformed the market, losing about 11.4% since the beginning of the year compared to the S&P 500's decline of 3.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.72 on revenues of $6.75 billion, and for the current fiscal year, it is $10.12 on revenues of $26.42 billion [7] - The estimate revisions trend for Marriott is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Hotels and Motels industry is currently ranked in the top 37% of over 250 Zacks industries, suggesting that companies in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - Choice Hotels, a competitor in the same industry, is expected to report quarterly earnings of $1.38 per share, reflecting a year-over-year increase of 7.8% [9]

Company Performance - IQVIA Holdings reported quarterly earnings of $2.70 per share, exceeding the Zacks Consensus Estimate of $2.63 per share, and up from $2.54 per share a year ago, representing an earnings surprise of 2.66% [1] - The company posted revenues of $3.83 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.55%, compared to $3.74 billion in the same quarter last year [2] - Over the last four quarters, IQVIA has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance - IQVIA shares have declined approximately 22.5% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] - The current Zacks Rank for IQVIA is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $2.80 on revenues of $3.89 billion, and for the current fiscal year, it is $11.84 on revenues of $15.86 billion [7] - The outlook for the Medical - Instruments industry, in which IQVIA operates, is currently in the top 25% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Pediatrix Medical Group (MD) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32%. A quarter ago, it was expected that this physician group would post earnings of $0.37 per share when it actually produced earnings of $0.51, delivering a surprise of 37.84%.Over the last four quarters, t ...

Cabot (CBT) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $1.78 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 2.15%. A quarter ago, it was expected that this chemical company would post earnings of $1.80 per share when it actually produced earnings of $1.76, delivering a surprise of -2.22%. Over the last four quarters, the company ...

Core Viewpoint - Artivion (AORT) reported quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.12 per share, representing a 50% earnings surprise [1] - The company posted revenues of $98.98 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 4.19% [2] Financial Performance - Artivion's earnings of $0.06 per share are unchanged from the same quarter last year, and the company has surpassed consensus EPS estimates two times over the last four quarters [1][2] - The company has topped consensus revenue estimates three times in the last four quarters, with year-ago revenues of $97.43 million [2] Stock Performance - Artivion shares have declined approximately 18.4% since the beginning of the year, compared to a decline of 3.3% for the S&P 500 [3] - The current Zacks Rank for Artivion is 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $108.7 million, and for the current fiscal year, it is $0.68 on revenues of $426.65 million [7] - The outlook for the Medical - Instruments industry is positive, ranking in the top 28% of over 250 Zacks industries, suggesting potential for outperformance [8]

Core Viewpoint - Sterling Infrastructure (STRL) reported quarterly earnings of $1.63 per share, exceeding the Zacks Consensus Estimate of $1.58 per share, and showing an increase from $1 per share a year ago, indicating a positive earnings surprise of 3.16% [1] Financial Performance - The company achieved revenues of $430.95 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.69%, although this represents a decline from year-ago revenues of $440.36 million [2] - Over the last four quarters, Sterling Infrastructure has consistently surpassed consensus EPS estimates, achieving this four times [2] Stock Performance - Since the beginning of the year, Sterling Infrastructure shares have decreased by approximately 1.7%, while the S&P 500 has declined by 3.3%, indicating relative outperformance [3] Future Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $2.14 on revenues of $535.3 million, and for the current fiscal year, it is $8.21 on revenues of $2.03 billion [7] Industry Context - The Engineering - R and D Services industry, to which Sterling Infrastructure belongs, is currently ranked in the top 15% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Core Viewpoint - Vertex Pharmaceuticals reported quarterly earnings of $4.06 per share, missing the Zacks Consensus Estimate of $4.22 per share, and showing a decline from $4.76 per share a year ago, indicating an earnings surprise of -3.79% [1] - The company posted revenues of $2.77 billion for the quarter, missing the Zacks Consensus Estimate by 1.72%, but showing an increase from $2.69 billion year-over-year [2] Financial Performance - Over the last four quarters, Vertex has surpassed consensus EPS estimates only once, and has topped consensus revenue estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is $4.25 on revenues of $2.89 billion, and for the current fiscal year, it is $17.69 on revenues of $11.86 billion [7] Market Performance - Vertex shares have increased by approximately 24.5% since the beginning of the year, contrasting with a -3.3% decline in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Outlook - The Medical - Biomedical and Genetics industry is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook as the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - Syndax Pharmaceuticals reported a quarterly loss of $0.98 per share, which was better than the Zacks Consensus Estimate of a loss of $1.04, indicating an earnings surprise of 5.77% [1] Financial Performance - The company posted revenues of $20.04 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 36.69%, compared to zero revenues a year ago [2] - The current consensus EPS estimate for the upcoming quarter is -$0.99 on revenues of $17.81 million, and for the current fiscal year, it is -$3.99 on revenues of $81.74 million [7] Stock Performance - Syndax shares have increased by approximately 3.9% since the beginning of the year, while the S&P 500 has declined by 3.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Syndax belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Company Performance - TG Therapeutics reported quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18 per share, compared to a loss of $0.07 per share a year ago, representing an earnings surprise of -83.33% [1] - The company posted revenues of $120.86 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.99%, and showing a significant increase from year-ago revenues of $63.47 million [2] - Over the last four quarters, TG Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance - TG Therapeutics shares have increased approximately 44.3% since the beginning of the year, while the S&P 500 has declined by -3.3% [3] - The current consensus EPS estimate for the coming quarter is $0.22 on revenues of $131.03 million, and for the current fiscal year, it is $0.98 on revenues of $545.6 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which TG Therapeutics belongs, is currently in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]